What is the best alternative treatment for anxiety in an 82‑year‑old patient who is already taking alprazolam (Xanax) and has severe anxiety?

Switch from Alprazolam to an SSRI or SNRI

For an 82-year-old with severe anxiety already taking alprazolam (Xanax), the best alternative is to transition to an SSRI (such as escitalopram or sertraline) or SNRI, while gradually tapering the benzodiazepine. Alprazolam poses particularly high risks in elderly patients, including cognitive impairment, falls with fractures, dependence, and challenging withdrawal syndromes 1, 2.

Why Alprazolam Is Problematic in This Patient

The 2019 AGS Beers Criteria explicitly recommends avoiding benzodiazepines in older adults due to increased sensitivity, substantial risk of cognitive impairment, delirium, falls, fractures, and motor vehicle accidents 1. Alprazolam specifically carries additional concerns:

• High abuse and dependence potential due to its rapid onset and short half-life 3
• More intense withdrawal symptoms compared to other benzodiazepines 4
• Greater cognitive impairment risk than longer-acting, lower-potency alternatives 4
• Sedation and falls risk that increases with age 2, 1

The FDA label confirms increased digoxin toxicity risk when alprazolam is used in geriatric patients, and warns of sedation, respiratory depression, and withdrawal in vulnerable populations 5.

Recommended Treatment Algorithm

Step 1: Initiate an SSRI or SNRI

Start a first-line antidepressant for anxiety while the patient is still on alprazolam:

• Escitalopram: Start 5 mg daily (half the usual adult starting dose) 6
• Sertraline: Start 25 mg daily 6
• Paroxetine: Start 10 mg daily (though more anticholinergic than other SSRIs) 6

Rationale: SSRIs are evidence-based first-line treatments for anxiety disorders 7, 8. Starting at low doses in elderly patients minimizes initial anxiety exacerbation and improves adherence 9. The delayed onset (4-8 weeks) necessitates maintaining the benzodiazepine temporarily 6, 9.

Step 2: Titrate SSRI/SNRI to Therapeutic Dose

Increase by the initial dose increment every 5-7 days as tolerated 6:

• Monitor for efficacy and side effects weekly during titration
• Target therapeutic doses: escitalopram 10-20 mg, sertraline 50-200 mg 6
• Continue alprazolam at current dose during this phase

Step 3: Begin Alprazolam Taper (After 4-6 Weeks on SSRI/SNRI)

Once the antidepressant reaches therapeutic levels and shows benefit:

Taper benzodiazepines gradually using a 25% dose reduction every 1-2 weeks 7. This schedule has demonstrated safety and moderate success 7.

Critical: Abrupt withdrawal can cause rebound anxiety, hallucinations, seizures, delirium tremens, and rarely death 7. The CDC explicitly recommends tapering opioids before benzodiazepines when both are prescribed due to greater benzodiazepine withdrawal risks 7—this same caution applies to benzodiazepine discontinuation in general.

Step 4: Consider Adjunctive Cognitive Behavioral Therapy

CBT significantly increases benzodiazepine taper success rates and helps patients struggling with discontinuation 7. If available, initiate CBT early in the treatment plan 8.

Alternative Pharmacologic Options (If SSRIs Fail or Are Contraindicated)

Second-Line: Buspirone

• Start 5 mg twice daily, maximum 20 mg three times daily 6
• Advantages: No dependence, no cognitive impairment, no withdrawal
• Disadvantages: Takes 2-4 weeks to work; only effective for mild-moderate anxiety 6

Third-Line: Pregabalin

• Approved in Europe for GAD 10
• Better side-effect profile than benzodiazepines
• Requires renal dose adjustment in elderly patients

Consider With Caution: Quetiapine

Recent evidence shows quetiapine (atypical antipsychotic) has efficacy for GAD 10. However:

• Oral quetiapine had the best safety profile among medications for severe agitation in elderly ED patients 11
• Approximately 50% tolerate side effects (mainly sedation/fatigue) 10
• The 2019 Beers Criteria recommend avoiding antipsychotics for behavioral control in dementia due to increased mortality risk 1, 2
• Reserve for refractory cases under specialist supervision

What NOT to Do

Do not switch to lorazepam or other benzodiazepines as a "better" alternative. While NICE guidelines suggest lorazepam 0.25-0.5 mg in elderly patients (maximum 2 mg/24 hours) for acute anxiety 12, this is for acute symptom management, not chronic treatment. The 2021 Mayo Clinic guidelines explicitly list benzodiazepines under medications to deprescribe in older adults 2.

Do not use long-acting benzodiazepines (diazepam) due to accumulation and toxicity 1.

Avoid combining benzodiazepines with opioids if the patient takes any pain medications—this quadruples overdose death risk 13, 7.

Common Pitfalls to Avoid

1. Starting SSRI at full adult dose: This exacerbates anxiety initially and reduces adherence 9
2. Tapering alprazolam too quickly: The 25% every 1-2 weeks schedule is evidence-based; faster tapers increase withdrawal severity 7
3. Stopping alprazolam before SSRI takes effect: Maintain benzodiazepine coverage for 4-6 weeks while antidepressant reaches therapeutic levels 9
4. Not warning about withdrawal symptoms: Educate patient that anxiety may temporarily worsen during taper—this is expected and manageable 7
5. Ignoring reversible causes: Rule out hypoxia, urinary retention, constipation, medication effects, and undertreated pain before escalating psychiatric medications 12

Monitoring During Transition

• Weekly visits during first month to assess adherence, side effects, and anxiety levels 8
• Monthly follow-up until symptoms stabilize 8
• Check for concurrent medications that interact with SSRIs (especially if on digoxin, warfarin, or other narrow therapeutic index drugs) 5
• Monitor for falls, confusion, or worsening function throughout the taper

This approach prioritizes long-term safety and efficacy over short-term symptom control, addressing both the inadequate anxiety management and the substantial risks alprazolam poses in an 82-year-old patient.